Literature DB >> 19587464

Current treatment strategy in the management of vestibular schwannoma.

Basant K Misra1, Harshad R Purandare, Rahul S Ved, Anshul A Bagdia, Pandurang B Mare.   

Abstract

BACKGROUND: The changing trends in the management of vestibular schwannoma (VS) in our practice over the last two decades as well as the current status are presented here.
MATERIALS AND METHODS: The observations are based on the experience of 559 consecutive cases of VS operated by the first author between 1987 and 2008, 438 of which were operated by microsurgery and 139 by gamma knife radiosurgery (GKR) (18 of which were previously operated by the authors). A detailed analysis of microsurgically managed patients in two different periods (100 consecutive patients each before 1993 and 2008) were compared to see the changing trend and document current results. RESULTS AND DISCUSSION: In the initial experience (1990s), the emphasis in microsurgery was preserving life, total excision of tumor and preservation of function in that order. In the 21 st century, the emphasis in microsurgery has been all about functional preservation. In 100 consecutive cases of VS (excluding neurofibromatosis-2) that were treated microsurgically between 2005-08, there were four small tumors (<2 cm), 14 medium-sized tumors (2-3 cm) and 82 large tumors (>or=3 cm). The total excision rate was 83%. The facial nerve anatomical preservation rate was 96% and function was Grade III House-Brackmann (HB) or better in 87%. Both the total excision rate and facial function of Grade II HB or better were 100% in cases with tumor size less than three cm. Functional hearing preservation was achieved in ten cases. There was no operative mortality.
CONCLUSION: Total excision of VS, though aimed at, is no more pursued at the cost of facial function. Moreover, microsurgery, radiosurgery and observation are all valid options in the management of VS and choosing the correct modality helps in achieving optimal outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19587464     DOI: 10.4103/0028-3886.53263

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  6 in total

1.  A Systematic Analysis of the Reliability of Diffusion Tensor Imaging Tractography for Facial Nerve Imaging in Patients with Vestibular Schwannoma.

Authors:  Nolan Ung; Monica Mathur; Lawrance K Chung; Nicole Cremer; Panayiotis Pelargos; Andrew Frew; Kimberly Thill; Ishani Mathur; Brittany Voth; Michael Lim; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2016-01-04

2.  Morbidity Rate of the Retrosigmoid versus Translabyrinthine Approach for Vestibular Schwannoma Resection.

Authors:  Sami Obaid; Ioannis Nikolaidis; Musaed Alzahrani; Robert Moumdjian; Issam Saliba
Journal:  J Audiol Otol       Date:  2018-08-22

3.  Nonvestibular Schwannoma Tumors in the Cerebellopontine Angle: A Single-Surgeon Experience.

Authors:  Vivek Kumar Kankane; Anshu Chandrakant Warade; Basant Kumar Misra
Journal:  Asian J Neurosurg       Date:  2019 Jan-Mar

4.  Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base section.

Authors:  Daniele Starnoni; Lorenzo Giammattei; Giulia Cossu; Michael J Link; Pierre-Hugues Roche; Ari G Chacko; Kenji Ohata; Majid Samii; Ashish Suri; Michael Bruneau; Jan F Cornelius; Luigi Cavallo; Torstein R Meling; Sebastien Froelich; Marcos Tatagiba; Albert Sufianov; Dimitrios Paraskevopoulos; Idoya Zazpe; Moncef Berhouma; Emmanuel Jouanneau; Jeroen B Verheul; Constantin Tuleasca; Mercy George; Marc Levivier; Mahmoud Messerer; Roy Thomas Daniel
Journal:  Acta Neurochir (Wien)       Date:  2020-07-29       Impact factor: 2.216

5.  Staging in giant vestibular schwannoma surgery: A two consecutive day technique for complete resection in basic neurosurgical setups.

Authors:  Deepak Bandlish; Nilay Biswas; Sumit Deb
Journal:  J Neurosci Rural Pract       Date:  2014-07

6.  Stereotactic Radiosurgery for Vestibular Schwannomas: Reducing Toxicity With 11 Gy as the Marginal Prescribed Dose.

Authors:  Guillaume Dupic; Marie Urcissin; Thierry Mom; Pierre Verrelle; Véronique Dedieu; Ioana Molnar; Youssef El-Ouadih; Vincent Chassin; Michel Lapeyre; Jean-Jacques Lemaire; Julian Biau; Toufic Khalil
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.